The Mafia of Pharma Pricing
US prescription drug prices are being driven up by opaque supply-chain middlemen known as pharmacy benefit managers (PBMs), which now sit inside vertically integrated insurance and healthcare conglomerates. Commenters describe how rebate schemes, lack of price transparency, regulatory loopholes, and Medicare’s limited bargaining power let PBMs and insurers profit while costs are passed through to patients, employers, and taxpayers. The thread contrasts the genuine high cost and risk of drug development with rent-seeking behaviors, data monetization, and regulatory capture, and suggests reforms such as banning certain vertical integrations, tightening anti-kickback rules, and mandating public price lists.
Role and Incentives of PBMs and Insurers
- PBMs are highly consolidated and often owned by large insurers/healthcare conglomerates.
- Because insurance profits are capped as a % of medical spend, shifting margin into PBMs circumvents caps: PBMs overcharge insurers, insurers raise premiums, the parent company keeps the spread.
- Insurers are not viewed as primary “victims”; they can pass costs to employers and patients and have weak incentives to push prices down.
- PBMs use secret rebates and formulary control to steer volume, keep generics off formularies, and justify high list prices while claiming big “discounts.”
Impact on Patients and Providers
- Insured patients usually pay copays, not list price, but ultimately bear costs through higher premiums and narrower coverage.
- Uninsured or temporarily “out-of-network” patients get hit with inflated list prices, e.g., insulin.
- Stories of doctors and urgent care pushing tests or devices seemingly aligned with manufacturer payments raise concerns about conflicts of interest.
- Some patients bypass the system via imports or buyers’ clubs, highlighting how broken the domestic market feels.
Data, IT, and Privacy Practices
- First-hand accounts describe PBMs as merger-heavy, technically messy organizations using “innovation labs” as client-facing theater.
- There is a substantial business in selling or “rebating” around de-identified or consent-waived medical data; posters question why this is legal but note HIPAA waivers and lobbying.
- Concerns about mandatory IDs/phone numbers, data leaks, and weak consequences for breaches.
Regulation, Capture, and System Design
- Multiple commenters frame the mess as regulatory design and capture: safe harbors for rebates, 340B distortions, Medicare’s limited price negotiation, import restrictions.
- Others counter that some regulation is necessary (safety/efficacy), and that the U.S. problem is bad or captured regulation, not regulation per se.
- Debate over whether vertical integration (insurer–PBM–pharmacy) should be explicitly prohibited.
Drug Costs, R&D, and Alternatives
- Biotech insiders emphasize real scientific difficulty and cost; others note heavy public funding, marketing outlays exceeding R&D in some cases, and patent games.
- Disagreement over whether high profit margins are justified by past R&D costs.
- Proposed remedies include price transparency, banning certain kickback exemptions, stronger antitrust, direct price regulation, or more public ownership/funding of drug development.